Wednesday, June 1, 2016
Gilead Sciences has announced two appointments to the company’s senior leadership team. Kevin Young, CBE, has been appointed chief operating officer, and Martin Silverstein, M.D., has been appointed executive vice president, Strategy. Both Young and Silverstein will report to John F. Milligan, Ph.D., president and chief executive officer. The company also announced that Paul R. Carter, executive vice president, Commercial Operations, has decided to depart Gilead and pursue other opportunities.
Envigo has appointed Scott Schulz, MBA, to the post of director, North American (NA) Operations. In this role, Schulz will optimize operational performance and service delivery across the company’s North American based production locations for Research Models and Services (RMS). He will report directly to Michael Caulfield, president North American RMS at Envigo.
Total Clinical Trial Management (TCTM), a full service CRO, has appointed Timothy Evans vice president of Business Development. Evans will be joining the TCTM executive team and will have responsibility for leading strategic corporate and business development efforts internationally. [Read More]
The Medicines Company has appointed Tony Kingsley as president and chief operating officer. Kingsley will help oversee the day-to-day operations of the company and will lead the company’s commercial activities.
Intrexon, a provider of synthetic biology, has appointed Geno Germano to the new role of president of Intrexon effective June 1, reporting to Chairman and Chief Executive Officer Randal J. Kirk. As president, Germano will help lead Intrexon’s management team and commercialization efforts utilizing the company’s technology platform for biologically-based solutions across a broad range of industries. Each of Intrexon’s five sectors and the office of the chief operating officer will report to Germano.
SRI International, an independent, nonprofit R&D organization, has announced the hiring of two new executives. Greg Kovacs, M.D., Ph.D. has joined as president of SRI’s Biosciences Division and Erin Andre has joined as SRI’s chief people officer.
Wolfe Laboratories has expanded its senior management team through the addition of Paul Oakley, who has joined as senior vice president and general counsel. In this role, Oakley will be responsible for the company’s corporate and financial strategies and general operations. Oakley brings more than 20 years of experience as an executive and entrepreneur, building and managing high-growth, mission-oriented teams and organizations, as well as an external general counsel for a vast portfolio of emerging growth companies.
ORIG3N, a pioneer in the field of regenerative medicine, has added Melissa May as the company’s vice president of product strategy to establish partnerships and collaborations to bring in non-dilutive funding that will support R&D to develop future product offerings. In addition, May will play a role in the strategy and channel development of ORIG3N’s life science products, as well as LifeProfiles, which are genetic analysis available for consumers.
ICON, a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, has announced that, together with Pfizer, it has won the Clinical Research Team of the Year award at the inaugural Clinical and Research Excellence (CARE) Awards.